参考文献/References:
[1] Ruddy KJ,Sangaralingham LR,Houten HV,et al. Utilization of cardiac surveillance tests in survivors of breast cancer and lymphoma after anthracycline-based chemotherapy[J]. Circ Cardiovasc Qual Outcomes,2020,13(3):e005984.
[2] Narayan V,Thompson EW,Demissei B,et al. Mechanistic biomarkers informative of both cancer and cardiovascular disease:JACC state-of-the-art review[J]. J Am Coll Cardiol,2020,75(21):2726-2737.
[3] Capilupi MJ,Kerath SM,Becker LB. Vagus nerve stimulation and the cardiovascular system[J]. Cold Spring Harb Perspect Med,2020,10(2):a034173.
[4] Zahalka AH,Arnal-Estape A,Maryanovich M,et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer[J]. Science,2017,358(6361):321-326.
[5] Chen M,Zhou X,Yu L,et al. Low-level vagus nerve stimulation attenuates myocardial ischemic reperfusion injury by antioxidative stress and antiapoptosis reactions in canines[J]. J Cardiovasc Electrophysiol,2016,27(2):224-231.
[6] Shinlapawittayatorn K,Chinda K,Palee S,et al. Low-amplitude,left vagus nerve stimulation significantly attenuates ventricular dysfunction and infarct size through prevention of mitochondrial dysfunction during acute ischemia-reperfusion injury[J]. Heart Rhythm,2013,10(11):1700-1707.
[7] Curigliano G,Cardinale D,Dent S,et al. Cardiotoxicity of anticancer treatments:epidemiology,detection,and management[J]. CA Cancer J Clin,2016,66(4):309-325.
[8] Wang TJ,Evans JC,Benjamin EJ,et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community[J]. Circulation,2003,108(8):977-982.
[9] Fogarassy G,Vathy-Fogarassy ?,Kenessey I,et al. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer—a real-world data-based,nationwide classification analysis[J]. Int J Cardiol,2019,285:47-52.
[10] Salz T,Zabor EC,de Nully Brown P,et al. Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors[J]. J Clin Oncol,2017,35(34):3837-3843.
[11] Willis MS,Parry TL,Brown DI,et al. Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1[J]. Circ Heart Fail,2019,12(3): e005234.
[12] Feijen EAML,Font-Gonzalez A,van der Pal HJH,et al. Risk and temporal changes of heart failure among 5-year childhood cancer survivors:a DCOG-LATER study[J]. J Am Heart Assoc,2019,8(1):e009122.
[13] Bates JE,Howell RM,Liu Q,et al. Therapy-related cardiac risk in childhood cancer survivors:an analysis of the childhood cancer survivor study[J]. J Clin Oncol,2019,37(13):1090-1101.
[14] Conen D,Wong JA,Sandhu RK,et al. Risk of malignant cancer among women with new-onset atrial fibrillation[J]. JAMA Cardiol,2016,1(4):389-396.
[15] Amioka M,Sairaku A,Ochi T,et al. Prognostic significance of new-onset atrial fibrillation in patients with non-Hodgkin’s lymphoma treated with anthracyclines[J]. Am J Cardiol,2016,118(9):1386-1389.
[16] Benjanuwattra J,Siri-Angkul N,Chattipakorn SC,et al. Doxorubicin and its proarrhythmic effects:a comprehensive review of the evidence from experimental and clinical studies[J]. Pharmacol Res,2020,151:104542.
[17] Porta-Sánchez A,Gilbert C,Spears D,et al. Incidence,diagnosis,and management of QT prolongation induced by cancer therapies:a systematic review[J]. J Am Heart Assoc,2017,6(12):e007724.
[18] Markman TM,Ruble K,Loeb D,et al. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy[J]. Pediatr Blood Cancer,2017,64(11).DOI: 10.1002/pbc.26556.Epub 2017 Apr 28.
[19] Wang Y,Po SS, Scherlag BJ,et al. The role of low-level vagus nerve stimulation in cardiac therapy[J]. Expert Rev Med Devices,2019,16(8):675-682.
[20] Yu L,Wang S,Zhou X,et al. Chronic intermittent low-level stimulation of tragus reduces cardiac autonomic remodeling and ventricular arrhythmia inducibility in a post-infarction canine model[J]. JACC Clin Electrophysiol,2016,2(3):330-339.
[21] Burka B,Herman E,Vick J. Role of the sympathetic nervous system in daunomycin-induced arrhythmia in the monkey[J]. Br J Pharmacol,1970,39(3):501-510.
[22] Guimar?es SL,Brand?o SC,Andrade LR,et al. Cardiac sympathetic hyperactivity after chemotherapy:early sign of cardiotoxicity?[J]. Arq Bras Cardiol,2015,105(3):228-234.
[23] Lon?ar-Turukalo T,Vasi? M,Tasi ? T,e t al. Heart rate dynamics in doxorubicin-induced cardiomyopathy[J]. Physiol Meas,2015,36(4):727-739.
[24] Poto?nik N,Per?e M,Cerar A,et al. Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment[J]. PLoS One,2017,12(7):e0181632.
[25] Wang Z,Yu L,Wang S,et al. Chronic intermittent low-level transcutaneous electrical stimulation of auricular branch of vagus nerve improves left ventricular remodeling in conscious dogs with healed myocardial infarction[J]. Circ Heart Fail,2014,7(6):1014-1021.
[26] Murabito A,Hirsch E,Ghigo A. Mechanisms of anthracycline-induced cardiotoxicity:is mitochondrial dysfunction the answer?[J]. Front Cardiovasc Med,2020,7:35.
[27] Zhang S,Liu X,Bawa-Khalfe T,et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med,2012,18(11):1639-1642.
[28] Rocca C,Pasqua T,Cerra MC,et al. Cardiac damage in anthracyclines therapy:focus on oxidative stress and inflammation[J]. Antioxid Redox Signal,20 20,32(15):1081-1097.
[29] Kong SS,Liu JJ,Yu XJ,et al. Protection against ischemia-induced oxidative stress conferred by vagal stimulation in the rat heart:involvement of the AMPK-PKC pathway[J]. Int J Mol Sci,2012,13(11):14311-14325.
[30] Yi C,Zhang C,Hu X,et al. Vagus nerve stimulation attenuates myocardial ischemia/reperfusion injury by inhibiting the expression of interleukin-17A[J]. Exp Ther Med,2016,11(1):171-176.
[31] Krysko DV, Kaczmarek A,Krysko O,et al. TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation[J]. Cell Death Differ,2011,18(8):1316-1325.
[32] Yao Y,Xu X,Zhang G,et al. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway[J]. Basic Res Cardiol,2012,107(3):267.
[33] Nozaki N,Shishido T,Takeishi Y,et al. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice[J]. Circulation,2004,110(18):2869-2874.
[34] Reardon C,Murray K,Lomax AE. Neuroimmune communication in health and disease[J]. Physiol Rev,2018,98(4):2287-2316.
[35] Yu L,Huang B,Po SS,et al. Low-level tragus stimulation for the treatment of ischemia and reperfusion injury in patients with ST-segment elevation myocardial infarction:a proof-of-concept study[J]. JACC Cardiovasc Interv,2017,10(15):1511-1520.
[36] Stavrakis S,Humphrey MB,Scherlag BJ,et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation[J]. J Am Coll Cardiol,2015,65(9):867-875.
[37] Marinello J,Delcuratolo M,Capranico G. Anthracyclines as topoisomerase Ⅱ poisons:from early studies to new perspectives[J]. Int J Mol Sci,2018,19(11):3480.
[38] Nuntaphum W,Pongkan W,Wongjaikam S,et al. Vagus nerve stimulation exerts cardioprotection against myocardial ischemia/reperfusion injury predominantly through its efferent vagal fibers[J]. Basic Res Cardiol,2018,113(4):22.
[39] Xue RQ,Sun L,Yu XJ,et al. Vagal nerve stimulation improves mitochondrial dynamics via an M3 receptor/CaMKK β/AMPK pathway in isoproterenol-induced myocardial ischaemia[J]. J Cell Mol Med,2017,21(1):58-71.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(3):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(3):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(3):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]